SCHEMBL3490332

SCHEMBL3490332

COc1ccccc1N1C(=O)N(Cc2ccccc2)c2cc(Cl)cc(N3CCNCC3)c2S1(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.47
HCRTR2 O43614 1/20 0.47
HTR6 P50406 5/20 0.46
HTR3E A5X5Y0 2/20 0.46
HTR3B O95264 2/20 0.46
HTR3A P46098 2/20 0.46
HTR3D Q70Z44 2/20 0.46
HTR3C Q8WXA8 2/20 0.46
ADRB1 P08588 1/20 0.46
DRD2 P14416 1/20 0.46
CYP2C19 P33261 1/20 0.46
DRD3 P35462 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 1/20 0.46
HTR7 P34969 3/20 0.42
HTR1A P08908 2/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490797 0.91 HCRTR1 (0.48) HCRTR1HCRTR2HTR6DRD2DRD3
SCHEMBL3490715 0.86 HTT (0.51) HCRTR1HCRTR2HTR3EHTR3BHTR3A
SCHEMBL3489321 0.86 HTR3E (0.43) HCRTR1HCRTR2HTR6HTR3EHTR3B
SCHEMBL3489612 0.86 HCRTR1 (0.46) HCRTR1HCRTR2HTR6HTR3AADRB1
SCHEMBL3490544 0.86 MAPT (0.45) HCRTR1HCRTR2HTR6HTR3EHTR3B
SCHEMBL3489094 0.85 HCRTR2 (0.53) HCRTR1HCRTR2MAPT
SCHEMBL3490431 0.82 HTR3A (0.42) HTR6HTR3EHTR3BHTR3AHTR3D
SCHEMBL3489858 0.81 HTR6 (0.45) HTR6HTR3AADRB1SIGMAR1MAPT
SCHEMBL3489119 0.81 HTR6 (0.43) HTR6ADRB1DRD2DRD3SIGMAR1
SCHEMBL3490336 0.80 CMA1 (0.44) HTR6CYP2C19SIGMAR1LMNASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US claimed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D HCRTR1 131/4885HCRTR2 138/4885HTR6 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.